FeesSafety
Pluang+

Sanofi's Pompe disease drug shortage persists over 3 months due to manufacturing issues, risking patient health.

Market News
19 Nov 2026, 20:55 WIB
CNBC
View Source
Bearish
Sanofi's Pompe disease drug shortage persists over 3 months due to manufacturing issues, risking patient health.

Sanofi is facing a drug shortage for its Pompe disease treatments due to manufacturing problems at its Ireland facility, causing infusion cancellations for patients. The shortage has lasted over three months, with shipping delays expected to continue through November in the U.S. Pompe disease patients rely on Sanofi's enzyme replacement therapies to manage their condition, and interruptions risk serious health declines. The FDA is involved and has issued warnings to Sanofi, while the company works to restore supply and improve communication with patients and advocacy groups.

Sanofi SA has a market cap of $113.83 billion and a dividend yield of 5.13% as of Nov 20, 2026 02:11 WIB. Despite the ongoing drug shortage issues reported, the stock price on Pluang is USD 46.00, down 2.38% for the day, with all recent order activity being buys. The typical hold time for Sanofi shares on Pluang is 95 days, indicating steady investor interest amid the supply challenges.

More News (SNY)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App